Home » Stocks » Akebia Therapeutics

Akebia Therapeutics, Inc. (AKBA)

Stock Price: $10.50 USD 0.22 (2.14%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $10.50 0.00 (-0.01%) Aug 12, 4:00 PM

Stock Price Chart

Key Info

Market Cap 1.48B
Revenue (ttm) 340.15M
Net Income (ttm) -385.57M
Shares Out 143.32M
EPS (ttm) -3.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $10.50
Previous Close $10.28
Change ($) 0.22
Change (%) 2.14%
Day's Open 10.33
Day's Range 9.99 - 10.54
Day's Volume 1,390,925
52-Week Range 2.99 - 13.71

More Stats

Market Cap 1.48B
Enterprise Value 1.29B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 143.32M
Float 114.77M
EPS (basic) -3
EPS (diluted) -3.06
FCF / Share -1.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.64M
Short Ratio 8.68
Short % of Float 7.69%
Beta 1.40
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.36
PB Ratio 3.99
Revenue 340.15M
Operating Income -383.74M
Net Income -385.57M
Free Cash Flow -136.31M
Net Cash 194.15M
Net Cash / Share 1.37
Gross Margin 7.80%
Operating Margin -112.81%
Profit Margin -113.40%
FCF Margin -40.07%
ROA -15.19%
ROE -86.68%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$17.25*
(64.29% upside)
Low
12.0
Current: $10.50
High
26.0
Target: 17.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue3352081811.54----
Revenue Growth61.26%14.63%11706.32%-----
Gross Profit1902001811.54----
Operating Income-286-178-76.67-136-61.51-37.94-15.93-8.52
Net Income-280-144-73.67-136-60.72-37.03-13.17-8.20
Shares Outstanding11858.0443.5037.7226.4715.410.540.41
Earnings Per Share-2.36-2.47-1.69-3.60-2.29-8.04-126.94-27.82
Operating Cash Flow-257-97.49-56.1657.91-52.41-27.48-11.33-7.21
Capital Expenditures-6.66-1.61-1.62-2.66-0.41-0.23-0.02-
Free Cash Flow-264-99.10-57.7855.24-52.82-27.71-11.35-7.21
Cash & Equivalents14832231826013810932.561.64
Total Debt10315.00------
Net Cash / Debt44.3630731826013810932.561.64
Assets77199736430014311134.672.24
Liabilities37636124223211.946.923.914.92
Book Value39563612368.12131104-127-59.59
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Akebia Therapeutics, Inc.
Country United States
Employees 358
CEO John P. Butler

Stock Information

Ticker Symbol AKBA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AKBA
IPO Date March 20, 2014

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.